Data obtained from a phase 3 trial showed that patients had an overall survival benefit of 14.1% with overall survival of 62.7% at five years for those receiving the Multikine treatment regimen followed by surgery and radiotherapy therapy, but not chemotherapy, as part of their standard of care. No safety issues were observed for Multikine in the treated population, according to the company.
CEL-SCI said it plans to seek US Food and Drug Administration approval for Multikine based on the immunotherapy's demonstrated significant overall survival benefit and favorable safety profile.
Price: 18.00, Change: -7.08, Percent Change: -28.23
|MiMedx Says Glass Lewis Recommends in Favor of Direc...|
|T2 Biosystems Says It Secured US Patent Covering Met...|
|TherapeuticsMD Gets FDA Approval for Supplemental Ne...|
|Deere Raises Fiscal 2022 Profit Outlook After Postin...|
|Covetrus Says it Gets Proposal From Clayton, Dubilie...|